Cargando…

Economic Evaluation of Tirbanibulin for the Treatment of Actinic Keratosis in Scotland

BACKGROUND: Tirbanibulin 1% ointment is a new treatment for actinic keratosis (AK) on the face or scalp. A health economic model was developed as part of a submission to the Scottish Medicines Consortium to evaluate the cost-effectiveness of tirbanibulin compared to the most frequently prescribed tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Dymond, Amy, Green, Will, Edwards, Mary, Pont, Maria Angeles Lopez, Gupta, Girish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10170011/
https://www.ncbi.nlm.nih.gov/pubmed/37012513
http://dx.doi.org/10.1007/s41669-023-00410-5
_version_ 1785039150081114112
author Dymond, Amy
Green, Will
Edwards, Mary
Pont, Maria Angeles Lopez
Gupta, Girish
author_facet Dymond, Amy
Green, Will
Edwards, Mary
Pont, Maria Angeles Lopez
Gupta, Girish
author_sort Dymond, Amy
collection PubMed
description BACKGROUND: Tirbanibulin 1% ointment is a new treatment for actinic keratosis (AK) on the face or scalp. A health economic model was developed as part of a submission to the Scottish Medicines Consortium to evaluate the cost-effectiveness of tirbanibulin compared to the most frequently prescribed treatments. METHODS: A decision tree approach was used to calculate the costs and benefits of different treatment strategies for AK on the face or scalp over a one-year time horizon. Data on the relative efficacy of treatments, which were based on the probability of complete clearance of AK, were obtained from a network meta-analysis. Sensitivity and scenario analyses were performed to determine the robustness of the model results. RESULTS: Tirbanibulin is estimated to be cost saving versus diclofenac sodium 3%, imiquimod 5% and fluorouracil 5%. Tirbanibulin remains cost saving when inputs are varied in sensitivity and scenario analyses. While the complete clearance rates are deemed similar across comparators, tirbanibulin is associated with a lower rate of severe local skin reactions, and a shorter treatment duration, which may improve treatment adherence. CONCLUSIONS: Tirbanibulin is a cost saving intervention for the treatment of AK from the perspective of the Scottish Healthcare System. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s41669-023-00410-5.
format Online
Article
Text
id pubmed-10170011
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-101700112023-05-11 Economic Evaluation of Tirbanibulin for the Treatment of Actinic Keratosis in Scotland Dymond, Amy Green, Will Edwards, Mary Pont, Maria Angeles Lopez Gupta, Girish Pharmacoecon Open Original Research Article BACKGROUND: Tirbanibulin 1% ointment is a new treatment for actinic keratosis (AK) on the face or scalp. A health economic model was developed as part of a submission to the Scottish Medicines Consortium to evaluate the cost-effectiveness of tirbanibulin compared to the most frequently prescribed treatments. METHODS: A decision tree approach was used to calculate the costs and benefits of different treatment strategies for AK on the face or scalp over a one-year time horizon. Data on the relative efficacy of treatments, which were based on the probability of complete clearance of AK, were obtained from a network meta-analysis. Sensitivity and scenario analyses were performed to determine the robustness of the model results. RESULTS: Tirbanibulin is estimated to be cost saving versus diclofenac sodium 3%, imiquimod 5% and fluorouracil 5%. Tirbanibulin remains cost saving when inputs are varied in sensitivity and scenario analyses. While the complete clearance rates are deemed similar across comparators, tirbanibulin is associated with a lower rate of severe local skin reactions, and a shorter treatment duration, which may improve treatment adherence. CONCLUSIONS: Tirbanibulin is a cost saving intervention for the treatment of AK from the perspective of the Scottish Healthcare System. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s41669-023-00410-5. Springer International Publishing 2023-04-03 /pmc/articles/PMC10170011/ /pubmed/37012513 http://dx.doi.org/10.1007/s41669-023-00410-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research Article
Dymond, Amy
Green, Will
Edwards, Mary
Pont, Maria Angeles Lopez
Gupta, Girish
Economic Evaluation of Tirbanibulin for the Treatment of Actinic Keratosis in Scotland
title Economic Evaluation of Tirbanibulin for the Treatment of Actinic Keratosis in Scotland
title_full Economic Evaluation of Tirbanibulin for the Treatment of Actinic Keratosis in Scotland
title_fullStr Economic Evaluation of Tirbanibulin for the Treatment of Actinic Keratosis in Scotland
title_full_unstemmed Economic Evaluation of Tirbanibulin for the Treatment of Actinic Keratosis in Scotland
title_short Economic Evaluation of Tirbanibulin for the Treatment of Actinic Keratosis in Scotland
title_sort economic evaluation of tirbanibulin for the treatment of actinic keratosis in scotland
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10170011/
https://www.ncbi.nlm.nih.gov/pubmed/37012513
http://dx.doi.org/10.1007/s41669-023-00410-5
work_keys_str_mv AT dymondamy economicevaluationoftirbanibulinforthetreatmentofactinickeratosisinscotland
AT greenwill economicevaluationoftirbanibulinforthetreatmentofactinickeratosisinscotland
AT edwardsmary economicevaluationoftirbanibulinforthetreatmentofactinickeratosisinscotland
AT pontmariaangeleslopez economicevaluationoftirbanibulinforthetreatmentofactinickeratosisinscotland
AT guptagirish economicevaluationoftirbanibulinforthetreatmentofactinickeratosisinscotland